The company is building ex vivo research and discovery platforms, leveraging expertise in microbiology and artificial intelligence, to analyze the symbiotic relationship between the microbiota and the human intestine. NovoSift is designed to mimic human intestinal physiology and unlock new insights into disease pathophysiology and reveal novel drug targets, compounds, and live biotherapeutic drug candidates.

NovoBiome's first drug candidate, ADC-001, for nonalcoholic fatty liver disease and nonalcoholic steato-hepatitis, is made of an anti-inflammatory bacterium with demonstrated in vitro and preclinical potency. The company aims to begin human clinical trials by 2022-2023.

New intestine chips promote precision in preclinical models
A new intestine-on-a-chip platform enables researchers to model host-microbiome relationships to gain new insights into the mechanisms of infectious disease...

Microbes shape antibodies prior to infection
Genetic analysis of antibodies reveals how microbes in the intestines impact overall B-cell populations and humoral responses to pathogens. The research...